Pyomyositis caused by Salmonella enterica: a rare case report

Read full text Summarise with VIRAT
Authors: B. Vijay Kumar, G. Vamshi Nandan Rao, M. Veena, Monalisa Sahu, K. Shivaram Rao
Cited by: 0
References: 11

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Pyomyositis is characterized as a primary bacterial infection of skeletal muscle, with Staphylococcus aureus being the most prevalent causative agent. In contrast, pyomyositis attributed to Salmonella enterica is an uncommon occurrence, typically observed in immunocompromised individuals, and often presents diagnostic challenges due to atypical laboratory findings. We report a such rare case involving an 82-year-old male who presented with severe bilateral thigh pain and difficulty in ambulation and a history of diabetes. He was admitted with provisional diagnosis of myositis. Laboratory evaluations indicated marked leukocytosis, elevated inflammatory markers, and hypoalbuminemia. These elevated inflamatory markers and MRI findings collectively suggested the possibility of pyomyositis with myonecrosis. Automated blood culture bactifast confirmed the presence of Salmonella enterica. In light of the diagnosis of pyomyositis caused by Salmonella enterica, prolonged intravenous antimicrobial therapy and supportive care were commenced. Following the appropriate administration of antibiotic treatment, the patient gradually exhibited symptomatic improvement and achieved hemodynamic stability. Early imaging and prompt initiation of aggressive antimicrobial therapy are essential for achieving favorable outcomes.

Fields of Study & Subjects

Streptococcal Infections and Treatments Orthopedic Infections and Treatments Salmonella and Campylobacter epidemiology

Publication details

Journal / source
International Journal of Research in Medical Sciences
Volume
14
Issue
4
Pages
1669–1672
Publication date
30 March 2026
Language
EN